Joshua M. Eizen - Nov 4, 2024 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Chief Operating Officer and Chief Legal Officer
Signature
/s/ Lucy Day, Attorney-in-Fact for Joshua M. Eizen
Stock symbol
ANTX
Transactions as of
Nov 4, 2024
Transactions value $
$0
Form type
4
Date filed
11/5/2024, 04:51 PM
Previous filing
Jul 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANTX Common Stock Award $0 +31.5K +33.22% $0.00 126K Nov 4, 2024 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANTX Stock Option (right to buy) Award $0 +63K $0.00 63K Nov 4, 2024 Common Stock 63K $1.08 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units ("RSUs"). RSUs vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024 until fully vested on November 4, 2028, subject to the Reporting Person's continuous service as of such date.
F2 Includes (a) a balance of 30,000 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024 and (b) a balance of 60,000 RSUs which vest as follows: 1/4th of the RSUs vest on January 1, 2025, 1/2 of the RSUs vest on January 1, 2026 and 1/4th of the RSUs vest on July 1, 2026, subject to the Reporting Person's continuous service as of such date.
F3 Reflects the adjusted total which includes the purchase of 2,386 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2024 and 2 shares under the Issuer's 2022 Employee Stock Purchase Plan on September 30, 2024.
F4 The shares subject to the option are exercisable and vest as follows: 1/48th of the shares vest and becomes exercisable monthly over four years from November 4, 2024 until fully vested and exercisable on November 4, 2028, subject to the Reporting Person's continuous service as of such date.

Remarks:

Chief Operating Officer and Chief Legal Officer